HC Wainwright & Co. Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $60
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Buy rating and announces Price Target of $60.
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Buy rating and announces Price Target of $60.